The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

Dexcom is hoping to win FDA approval to begin selling its G7 continuous glucose monitor in the U.S. later this year. (Shown here with an Apple Watch). · MedTech Dive · Courtesy of Dexcom The above ...

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong ...

Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. Dexcom warned patients ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

June 11 (Reuters) - Drug wholesaler Pharmsource LLC said it was unaware the Dexcom (DXCM.O), opens new tab glucose sensors it bought from licensed distributors had been ‌slated for destruction, after ...

DexCom, Inc. DXCM reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which beat the Zacks Consensus Estimate of 43 cents by 4.7%. The company had reported earnings of 50 cents ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It’s the longest-lasting wearable on the market. The G7 15 ...